J&J said it found no immediate procedure-related causes from the atrial fibrillation therapy but that risks can escalate if a ...

To predict arrhythmic risk in carriers of filamin C truncating variants, a novel risk predictive model was developed based on ...

Johnson & Johnson MedTech announced that it intends to resume the rollout of its Varipulse platform in the U.S. after a ...

(Reuters) -Johnson & Johnson said on Friday it resumed the limited market release of its Varipulse heart device in the United ...

"Johnson & Johnson to resume market release of Varipulse catheter in US" was originally created and published by Medical ...

The instructions for use have been updated to address issues that led to a greater risk of neurovascular events in an early ...

Johnson & Johnson will resume the limited market release of VARIPULSE in the United States after a comprehensive ...

Nearly six weeks after Johnson & Johnson paused the U.S. external evaluation of its Varipulse pulsed field ablation catheter ...

Johnson & Johnson is relaunching sales of a promising heart-rhythm device after a safety scare, but with a new warning for doctors that analysts say could hamper its market potential ...

A recent pause in U.S. sales of Varipulse is hampering the company’s bid to catch up in one of the industry’s fastest-growing ...

J.P. Morgan analysts said the findings of J&J’s investigation “could significantly hinder the product’s rollout in the U.S.

This summary covers recent health news, including Wyoming's first human H5N1 bird flu case, WHO's call for cancer warning ...